PODD - Insulet Corporation
| Previous Close | 180.89 |
| Open | 181.82 |
| Bid | 180.23 x 1100 |
| Ask | 180.52 x 1000 |
| Day's Range | 177.99 - 184.43 |
| 52 Week Range | 70.80 - 184.43 |
| Volume | 713,729 |
| Avg. Volume | 1,009,698 |
| Market Cap | 11.125B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | 697.52 |
| EPS (TTM) | 0.26 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 162.71 |
- Zacks
Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?
Insulet (PODD) has been gaining from several positive developments recently.
- Zacks
Insulet Rides on Omnipod's Wider Market Reach, New Products
Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.
- Thomson Reuters StreetEvents
Edited Transcript of PODD earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Insulet Corp Earnings Call
- Zacks
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
- Business Wire
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
- Investor's Business Daily
This IBD Stock Of The Day Just Bounded Above An Aggressive Buy Point
Insulet stock is the IBD Stock Of The Day after the diabetes treatment player smashed Wall Street's third-quarter estimates, raised its 2019 outlook and topped its 50-day moving average.
- Investor's Business Daily
Dow Jones Futures: Xerox-HP Deal Mulled; Match Group Dives; Roku, Carvana Earnings Due
Dow Jones futures signal another stock market rally pause. Xerox is mulling an HP takeover. Match Group is plunging on guidance. Roku, Carvna earnings are due.
- Zacks
Insulet (PODD) Surpasses Q3 Earnings and Revenue Estimates
Insulet (PODD) delivered earnings and revenue surprises of 200.00% and 7.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months ended September 30, 2019.
- Zacks
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
- Zacks
3 Medical Product Stocks Likely to Beat This Earnings Season
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
- Zacks
Why Earnings Season Could Be Great for Insulet (PODD)
Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
Insulet (PODD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Fiasp® Rapid Acting Insulin for Adults Now Approved for Use With the Omnipod Insulin Management System Platform in the United States
Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced FDA clearance for use of Fiasp® (fast-acting insulin aspart) with the Omnipod® Insulin Management System and the Omnipod DASH™ Insulin Management System for adults. Fiasp is a new-generation, ultra fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster than Novo Nordisk’s NovoLog®, so it more closely matches a body’s typical insulin response to a meal, thereby improving glycemic control.
- Simply Wall St.
These 4 Measures Indicate That Insulet (NASDAQ:PODD) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Zacks
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
Style Box ETF report for FNY
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Insulet Corporation (PODD)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Business Wire
Insulet to Announce Third Quarter 2019 Financial Results on November 5, 2019
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on November 5, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3163969. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
- Zacks
Insulet Receives FDA Approval for ACE Pump Implementation
FDA's approval will enable Insulet (PODD) to boost its insulin management business.
- Benzinga
Insulet's Insulin Delivery System Receives FDA Clearance As ACE Pump For Drug Infusion
The Massachusetts-based medical device company Insulet Corporation (NASDAQ: PODD ) said Monday that the FDA has approved its Alternate Controller Enabled Infusion, or ACE, pump. This allows Insulet to ...
- Zacks
Why Is Insulet (PODD) Up 17.3% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
Insulet (PODD) has various favorable factors to maintain the current high.
